Personalis PSNL 深 沪
等待开盘 08-08 09:30:00 美东时间
4.545
+0.140
+3.18%
华盛通- 最 高4.61
- 今 开4.47
- 成交量 153.37万股
- 最 低 4.285
- 昨 收 4.405
- 总市值 4.03亿
- 52周最高 7.79
- 市盈率 静 --
- 换手率 1.73%
- 52周最低 2.8262
- 委 比 15.52%
- 总股本 8867.71万
- 历史最高 53.46
- 量 比 1.11
- 振 幅 7.38%
- 历史最低 0.8906
- 每 手 1
- 风险率 1.02%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers BiomX (AMEX:PHGE) shares moved upwards by 40.1% to $0.61 during Tuesda...
08-06 05:07
Personalis shares are trading lower after the company reported a Q2 revenue miss, issued Q3 sales guidance below estimates, and cut its FY25 sales guidance.
Personalis shares are trading lower after the company reported a Q2 revenue mis...
08-06 04:04
Personalis Lowers FY2025 Sales Guidance from $80.000M-$90.000M to $70.000M-$80.000M vs $83.326M Est
Personalis (NASDAQ:PSNL) lowers FY2025 sales outlook from $80.000 million-$90.000 million to $70.000 million-$80.000 million vs $83.326 million estimate.
08-06 04:03
Personalis Sees Q3 Sales $12.000M-$14.000M vs $18.874M Est
Personalis (NASDAQ:PSNL) sees Q3 sales of $12.000 million-$14.000 million vs $18.874 million analyst estimate.
08-06 04:02
Earnings Scheduled For August 5, 2025
Companies Reporting Before The Bell • Silicon Laboratories (NASDAQ:SLAB) is exp...
08-05 16:32
Tempus gets FDA nod for Tempus ECG-Low EF
Tempus AI (NASDAQ:TEM) said that it has obtained 510((k)) clearance from the U.S. FDA for Tempus ECG-Low EF software. This software utilizes artificial intelligence to help identify patients who may ...
07-16 23:19
Cramer Says Tesla Dominates While Ouster Is 'Too Speculative'
Jim Cramer advises against investing in Tempus AI due to its ongoing losses and suggests Pan American as a profitable alternative. Insmed is also considered speculative while the only viable option for autonomous vehicles is Tesla. Ouster's stock was downgraded and other companies experienced mixed price action.
07-10 20:07
Personalis and Tempus Extend Partnership Through 2029, Add Colorectal Cancer To MRD Test Deal Covering Four Major Cancer Types
Collaboration extension through 2029 accelerates access to MRD technology across four major cancer typesPersonalis, Inc. (NASDAQ:PSNL) today announced an expansion and extension of its strategic collaboration with Tempus
07-10 04:01
Personalis Presents New Clinical Results From PREDICT DNA And SCANDARE Studies Highlighting Capabilities Of Ultrasensitive NeXT Personal ctDNA Blood Test For Monitoring And Predicting NAT Response In TNBC
Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced the presentation of new clinical results from the PREDICT DNA and SCANDARE studies highlighting the capabilities of its
06-03 04:02
Personalis Q1 2025 Earnings: Growth and Strategic Advances
Personalis (($PSNL)) has held its Q1 earnings call. Read on for the main highli...
05-08 08:19
